Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke
- 31 March 2017
- journal article
- review article
- Published by Springer Nature in Neurochemical Research
- Vol. 42 (9) , 2639-2645
Abstract
Stroke is the leading cause of serious long-term disability and the fifth leading cause of death in the United States. Treatment options for stroke are few in number and limited in efficacy. Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major component of stroke pathophysiology. Interfering with the inflammation cascade after stroke holds the promise to modulate stroke outcome. The calcium activated potassium channel KCa3.1 is expressed selectively in the injured CNS by microglia. KCa3.1 function has been implicated in pro-inflammatory activation of microglia and there is recent literature suggesting that this channel is important in the pathophysiology of ischemia/reperfusion (stroke) related brain injury. Here we describe the potential of repurposing Senicapoc, a KCa3.1 inhibitor, to intervene in the inflammation cascade that follows ischemia/reperfusion.Keywords
Funding Information
- Lundbeck Research USA (internal funding)
This publication has 49 references indexed in Scilit:
- KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivoCell Death & Disease, 2013
- TRAM-34, a Putatively Selective Blocker of Intermediate-Conductance, Calcium-Activated Potassium Channels, Inhibits Cytochrome P450 ActivityPLOS ONE, 2013
- Genetic KCa3.1-Deficiency Produces Locomotor Hyperactivity and Alterations in Cerebral Monoamine LevelsPLOS ONE, 2012
- The KCa3.1 Blocker TRAM-34 Reduces Infarction and Neurological Deficit in a Rat Model of Ischemia/Reperfusion StrokeJournal of Cerebral Blood Flow & Metabolism, 2011
- The immunology of stroke: from mechanisms to translationNature Medicine, 2011
- Therapeutic potential of KCa3.1 blockers: recent advances and promising trendsExpert Review of Clinical Pharmacology, 2010
- Inhibition of Reactive Astrocytes with Fluorocitrate Retards Neurovascular Remodeling and Recovery after Focal Cerebral Ischemia in MiceJournal of Cerebral Blood Flow & Metabolism, 2009
- Microglia in ischemic brain injuryFuture Neurology, 2009
- Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaBlood, 2008
- Selective Ablation of Proliferating Microglial Cells Exacerbates Ischemic Injury in the BrainThe Journal of Neuroscience, 2007